Investigators induced a type 2 diabetes model in rats using 10% fructose for two weeks followed by a single streptozotocin (STZ) injection (40 mg/kg). The study enrolled eighteen adult male Wistar rats, allocated equally to three groups: non-diabetic control (saline), STZ-diabetic (no treatment), and STZ-diabetic with metformin treatment. The treatment arm received 100 mg/kg/day of metformin for 30 days. The abstract did not report intermediate metabolic measurements such as blood glucose or insulin levels; those details were not provided in the source text.
This experimental design focused on alveolar bone outcomes rather than systemic metabolic endpoints. Investigators examined tissue-level and molecular changes in the alveolar process to evaluate how short-term metformin exposure modifies diabetic bone alterations in this model.
Tissue assessment included conventional histological and histomorphometric analysis of alveolar bone. Imaging used cone beam computed tomography (CBCT) to capture structural bone features, while molecular profiling relied on reverse transcription–polymerase chain reaction (RT‑PCR) for bone-related gene expression. The authors specifically measured expression of RunX2, osteocalcin, and COL1A1, genes linked to osteoblast differentiation, matrix production, and mineralization.
The multi-modal approach balanced morphological and genetic readouts. Histology and histomorphometry quantified cellular and matrix compartments, CBCT provided a radiographic correlate, and RT‑PCR offered insight into osteoblastic transcriptional programs under diabetic and treatment conditions.
Data indicated the STZ group experienced pronounced reductions in total bone area and osteoblast area compared with the non-diabetic control group. Gene expression of RunX2, osteocalcin, and COL1A1 was also decreased in untreated diabetic animals. In the group that received daily metformin, investigators reported significant improvements across these parameters relative to the STZ group.
Specifically, metformin increased total alveolar bone area and the area occupied by osteoblasts when compared to untreated diabetic rats. RT‑PCR results showed upregulation of RunX2, osteocalcin, and COL1A1 in metformin-treated animals versus the STZ group. The abstract did not provide numerical values, fold-changes, p-values, or confidence intervals; those statistics were not included in the source abstract and therefore are not stated here.
Despite measurable improvement with metformin, the treated animals did not achieve parity with the non-diabetic control group. The authors observed that bone area and osteoblastic gene expression remained lower than control levels after 30 days of metformin treatment, indicating partial recovery rather than complete normalization.
The study team interpreted the findings as evidence that metformin confers a short-term protective effect on alveolar bone in this STZ-induced T2DM rat model. The drug improved both histomorphometric indices and transcriptional markers associated with osteoblastic activity when compared to untreated diabetic animals. Investigators noted these changes occurred over a 30-day treatment window.
This partial rescue of bone morphology and gene expression suggests metformin influences local bone biology in the context of experimental diabetes, at least within the limits of the model and timeframe studied. The abstract did not report whether CBCT-derived measures paralleled histomorphometric changes in detail, nor did it provide systemic metabolic correlations.
Authors emphasized the short-term nature of this work and reported that metformin did not fully restore alveolar bone metrics to control levels. The abstract did not include longitudinal follow-up beyond the 30-day treatment, nor did it present systemic metabolic data such as glycemia, insulin, or inflammatory markers. Those omissions limit interpretation of whether structural and gene-level improvements result from direct local bone effects of metformin or from changes in systemic metabolic control.
Key unanswered questions remain: will longer treatment durations yield full restoration of bone parameters? Do CBCT findings quantitatively match histological measures? What systemic biochemical changes accompanied the skeletal outcomes? The source abstract did not provide these data. Future reports from the authors would need to supply numerical results, statistical testing, and extended time points to resolve these questions and clarify mechanisms underlying the observed partial protection.
Limitations recorded by the investigators included the brief treatment interval and the lack of reported metabolic measures in the abstract. These constraints should frame any interpretation of metformin’s effects on alveolar bone in this experimental T2DM setting.